ATE417609T1 - Zusammensetzungen von arginin mit kontrollierter freigabe - Google Patents

Zusammensetzungen von arginin mit kontrollierter freigabe

Info

Publication number
ATE417609T1
ATE417609T1 AT01950733T AT01950733T ATE417609T1 AT E417609 T1 ATE417609 T1 AT E417609T1 AT 01950733 T AT01950733 T AT 01950733T AT 01950733 T AT01950733 T AT 01950733T AT E417609 T1 ATE417609 T1 AT E417609T1
Authority
AT
Austria
Prior art keywords
arginine
compositions
controlled release
pahtways
biotransformation
Prior art date
Application number
AT01950733T
Other languages
English (en)
Inventor
Wayne Kaesemeyer
Original Assignee
Palmetto Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palmetto Pharmaceuticals Llc filed Critical Palmetto Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE417609T1 publication Critical patent/ATE417609T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT01950733T 2000-06-28 2001-06-28 Zusammensetzungen von arginin mit kontrollierter freigabe ATE417609T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60559900A 2000-06-28 2000-06-28

Publications (1)

Publication Number Publication Date
ATE417609T1 true ATE417609T1 (de) 2009-01-15

Family

ID=24424380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950733T ATE417609T1 (de) 2000-06-28 2001-06-28 Zusammensetzungen von arginin mit kontrollierter freigabe

Country Status (8)

Country Link
EP (1) EP1377284B1 (de)
JP (1) JP2004513877A (de)
AT (1) ATE417609T1 (de)
AU (1) AU2001271700A1 (de)
CA (1) CA2413816A1 (de)
DE (1) DE60137082D1 (de)
MX (1) MXPA03000194A (de)
WO (1) WO2002000212A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
EP1492508A4 (de) * 2002-03-04 2009-05-06 Teva Pharma Dosierformen mit kontrollierter freisetzung
WO2005035001A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
JP2010270111A (ja) * 2009-04-21 2010-12-02 Taisho Pharmaceutical Co Ltd アルギニン含有錠剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
ES2042292T3 (es) * 1989-03-17 1993-12-01 Pitman-Moore, Inc. Dispositivo de administracion de proteinas macromoleculares por liberacion controlada.
US5824331A (en) * 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US20020068365A1 (en) * 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
WO2000056328A1 (en) * 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
AU1800801A (en) * 1999-11-17 2001-05-30 Eric H. Kuhrts Exercise and muscle enhancement formulations

Also Published As

Publication number Publication date
EP1377284A4 (de) 2006-04-12
DE60137082D1 (de) 2009-01-29
CA2413816A1 (en) 2002-01-03
EP1377284A1 (de) 2004-01-07
WO2002000212A1 (en) 2002-01-03
JP2004513877A (ja) 2004-05-13
AU2001271700A1 (en) 2002-01-08
EP1377284B1 (de) 2008-12-17
MXPA03000194A (es) 2004-09-13

Similar Documents

Publication Publication Date Title
AU2603400A (en) Formulations for treating disease and methods of using same
AR023427A1 (es) Adhesivos de fundido en caliente basados en poliesteres sulfonados que incluyen un indicador de humedad.
CR20110356A (es) Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos (divisional exp. 8686)
IDP000022475A (id) Emulsi-mikro dan metoda
ATE306254T1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
GB2398726A (en) Mechanical fastening system for an absorbent article
AU144132S (en) Remote controller for massage chair
ATE327690T1 (de) Kleidungstück
HN2002000235A (es) Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización
DE60123114D1 (de) Verpackungsmittel zur aufnahme einer blisterpackung
DE60116359D1 (de) Kahalalid f formulierung
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
ES2189657B1 (es) Composiciones de resina plaguicidas.
ATE417609T1 (de) Zusammensetzungen von arginin mit kontrollierter freigabe
BR0213536A (pt) Formulações de xarope de ribavirina
CA96704S (en) Bottle
DE60110814D1 (de) Zusammensetzungen mit langsamer freigabe enthaltend lithium-carbonat
BR0010499A (pt) Agentes endoparasiticidas
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
DE50300694D1 (de) Desinfektionsmittel mit antiparasitärer Wirkung
AU2001274457A1 (en) Microcapsules containing arginine and the different uses thereof
MY135472A (en) Oil-barrier composition
AU2001236204A1 (en) Ironing device and iron
AU2687401A (en) Use of wood waste or extracts as insecticide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties